LRRK2
Les inhibiteurs de LRRK2 sont des composés qui ciblent et inhibent l'activité de la Leucine-Rich Repeat Kinase 2 (LRRK2), une enzyme impliquée dans plusieurs processus cellulaires, y compris l'autophagie, le trafic vésiculaire et l'inflammation. Les mutations du gène LRRK2 sont associées à un risque accru de développer la maladie de Parkinson, ce qui fait de LRRK2 une cible importante pour la recherche sur les maladies neurodégénératives. Les inhibiteurs de LRRK2 sont essentiels pour explorer son rôle dans la maladie de Parkinson et pour développer des stratégies thérapeutiques potentielles. Chez CymitQuimica, nous offrons une sélection d'inhibiteurs de LRRK2 pour soutenir vos recherches en neurodégénérescence, signalisation des kinases et développement thérapeutique.
42 produits trouvés pour "LRRK2"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
JH-II-127
CAS :JH-II-127 is an oral LRRK2 inhibitor with IC50s: 6.6 nM (WT), 2.2 nM (G2019S), 47.7 nM (A2016T).Formule :C19H21ClN6O3Degré de pureté :98.32%Couleur et forme :SolidMasse moléculaire :416.86Ref: TM-T7155
2mg43,00€5mg66,00€1mL*10mM (DMSO)73,00€10mg96,00€25mg166,00€50mg259,00€100mg366,00€200mg520,00€IKK 16
CAS :IKK 16 (IKK Inhibitor VII) is a selective IκB kinase (IKK) inhibitor for IKK-2, IKK complex and IKK-1 with IC50 of 40 nM, 70 nM and 200 nM, respectively.Formule :C28H29N5OSDegré de pureté :98.76% - 99.61%Couleur et forme :SolidMasse moléculaire :483.63Ref: TM-T6176
1mg38,00€2mg50,00€5mg84,00€1mL*10mM (DMSO)93,00€10mg132,00€25mg233,00€50mg385,00€100mg550,00€200mg782,00€CZC-25146
CAS :CZC-25146, a stable LRRK2 inhibitor, IC50: 4.76 nM (wild-type), 6.87 nM (G2019S).Formule :C22H25FN6O4SDegré de pureté :97.68%Couleur et forme :SolidMasse moléculaire :488.54GNE-9605
CAS :GNE-9605 is a highly effective, specifical, and brain-penetrant LRRK2 inhibitor (IC50: 19 nM).Formule :C17H20ClF4N7ODegré de pureté :98.55% - 98.75%Couleur et forme :SolidMasse moléculaire :449.83GNE-7915
CAS :GNE-7915 is a highly potent, selective and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) inhibitor.Formule :C19H21F4N5O3Degré de pureté :98% - ≥95%Couleur et forme :SolidMasse moléculaire :443.4Ref: TM-T1945
5mg44,00€1mL*10mM (DMSO)48,00€10mg58,00€25mg108,00€50mg177,00€100mg299,00€200mg389,00€500mg645,00€CZC-54252
CAS :CZC-54252 is a potent inhibitor of LRRK2.Formule :C22H25ClN6O4SDegré de pureté :99.39%Couleur et forme :SolidMasse moléculaire :504.99PF-06371900
CAS :PF-06371900 is a potent and highly selective inhibitor of leucine-rich repeat kinase 2 (LRRK2).Formule :C17H16N6O2SCouleur et forme :SolidMasse moléculaire :368.41LRRK2-IN-10
CAS :LRRK2-IN-10 (compound 34) is a potent, mutation-selective, brain-penetrant inhibitor targeting G2019S-LRRK2 kinase with IC50 values of 11 nM for G2019S-LRRK2Formule :C20H15N5ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :341.37PF-06455943
CAS :PF-06455943: LRRK2 inhibitor, IC50=3nM, PET radioligand, used for ADME/neuro PK & Parkinson's research.Formule :C17H14FN5OCouleur et forme :SolidMasse moléculaire :323.32LRRK2-IN-7
CAS :LRRK2-IN-7: potent, selective CNS-active LRRK2 inhibitor, IC50 0.9 nM, >1000x selectivity vs kinases/channels/CYPs.Formule :C24H26N6ODegré de pureté :99.26%Couleur et forme :SolidMasse moléculaire :414.5SRI-31255
CAS :SRI-31255 is an orally active LRRK2 inhibitor, with IC50 values of 520 nM for human wild-type (WT) and 427 nM for the G2019S mutant. It inhibits kinase activity by binding to the ATP-binding pocket of LRRK2, providing neuroprotective effects. SRI-31255 serves as a lead compound for developing LRRK2-targeted therapies for Parkinson’s disease research.Formule :C15H14N4Couleur et forme :SolidMasse moléculaire :250.30LRRK2-IN-12
CAS :LRRK2-IN-12 (compound 1) is a potent inhibitor of LRRK2 (G20195) with an IC 50 of 0.45 nM, LRRK2 WT with an IC 50 of 1.1 nM, and LRRK2 WT ADP-Glo with an IC 50 of 0.46 nM. This compound is utilized in research related to Alzheimer's Disease [1].Formule :C18H17ClN8O2Couleur et forme :SolidMasse moléculaire :412.83LRRK2-IN-20
CAS :LRRK2-IN-20 (EX. 4.64) is a selective inhibitor of LRRK2 with a potency of pIC50 at 0.7921 nM. This compound is applicable in research studies focused on Parkinson's Disease (PD).Formule :C24H32ClN7OCouleur et forme :SolidMasse moléculaire :470.01LRRK2-IN-13
CAS :LRRK2-IN-13 (Compound 13), with an IC50 value of 0.57 nM, serves as an inhibitor of LRRK2 and exhibits properties that allow it to penetrate the brain [1].Formule :C19H19ClN8O2Couleur et forme :SolidMasse moléculaire :426.86LRRK2-IN-14
CAS :LRRK2-IN-14 (Compound 8), an orally active inhibitor of LRRK2, exhibits an IC 50 of 6.3 nM against LRRK2(G2019S) cell activity and demonstrates inhibitory effects on hERG with an IC 50 of 22 μM. Additionally, LRRK2-IN-14 is permeable to the blood-brain barrier [1].Formule :C17H18F3N5O2Couleur et forme :SolidMasse moléculaire :381.35(R,R)-LRRK2-IN-7
CAS :(R,R)-LRRK2-IN-7 is an isomer of LRRK2-IN-7, a potent and selective LRRK2 kinase inhibitor with CNS penetrance. It exhibits an IC50 of 0.9 nM and demonstrates over 1000-fold selectivity compared to other kinases, ion channels, and CYP enzymes.Formule :C24H26N6OMasse moléculaire :414.50LRRK2-IN-3
CAS :LRRK2-IN-3: potent, selective oral LRRK2 blocker, BBB-penetrant, IC50 of 0.6 nM in hPBMCs, for Parkinson's research.Formule :C25H29ClF2N6O2Couleur et forme :SolidMasse moléculaire :518.99LRRK2-IN-4
CAS :LRRK2-IN-4: Potent, selective LRRK2 inhibitor, oral, BBB-penetrating, IC50=2.6 nM, potential for Parkinson's.Formule :C25H29ClF2N6O2Couleur et forme :SolidMasse moléculaire :518.99LRRK2-IN-2
CAS :LRRK2-IN-2: selective, potent LRRK2 inhibitor, IC50 of 0.6 nM, oral, crosses blood-brain barrier, for Parkinson's research.Formule :C23H23Cl2F3N6O2Couleur et forme :SolidMasse moléculaire :543.37LRRK2-IN-16
CAS :LRRK2-IN-16 (compound 25) is an inhibitor of the LRRK2 kinase with an IC50 value of less than 5 μM. It is applicable for research in neurodegenerative and autoimmune diseases.Formule :C18H19N5OSCouleur et forme :SolidMasse moléculaire :353.441
